Welcome to our dedicated page for YS Biopharma Co., Ltd. Warrants SEC filings (Ticker: YSBPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The YSBPW SEC filings page provides access to regulatory reports for the warrants of YS Biopharma Co., Ltd., a foreign private issuer whose ordinary shares trade as "YS" on the Nasdaq Capital Market. These filings, primarily on Form 6-K, document key corporate, financing and governance events that affect the company and its warrant holders.
Recent Form 6-K reports filed under the name LakeShore Biopharma Co., Ltd include disclosures about a US$15 million private placement financing involving ordinary shares and warrants, a subsequent change in control as an investor acquired a majority beneficial ownership stake, and fiscal year 2025 financial results. Other filings describe the receipt of preliminary and revised non-binding proposals to acquire the company and the formation of a special committee, along with the appointment of independent financial and legal advisors.
Through these SEC filings, users can follow how YS Biopharma funds the clinical development and future commercialization of its PIKA ae adjuvanted vaccine candidates and other biologics, and how ownership and control of the company evolve over time. The filings also show how specific transactions, such as private placements and warrant issuances, relate to the YSBPW warrants and the underlying ordinary shares.
On Stock Titan, these documents are updated from EDGAR in near real time and are paired with AI-powered summaries that explain the main points of each filing in clear language. Users can quickly understand the implications of current reports, financing announcements, acquisition proposals and other regulatory disclosures connected to YS Biopharma and its YSBPW warrants, without reading every page of the original SEC documents.
Amendment to Schedule 13D reporting that a consortium led by Oceanpine Investment, Oceanpine Capital and Crystal Investment has proposed a potential acquisition of all outstanding ordinary shares of LakeShore Biopharma Co., Ltd. The Revised Proposal values each ordinary share at US$0.86 in cash. Crystal Investment currently holds 21,021,332 shares (51.0%) based on 41,212,693 shares outstanding as of June 30, 2025. Oceanpine-held positions total 462,760 shares (1.1%), comprising 410,560 held by Oceanpine Investment and 52,200 by Oceanpine Capital.
The Consortium entered a Consortium Agreement providing for cooperative negotiation, exclusive collaboration among members for up to 24 months, and anticipated contributions of cash or shares to an acquisition vehicle. The Reporting Persons estimate approximately US$20,000,000 will be expended to acquire the publicly held shares at the Revised Proposal price. If consummated, the Proposed Transaction could result in delisting and termination of registration of the Ordinary Shares.
LakeShore Biopharma Co., Ltd. (Nasdaq: LSB / LSBPW) filed its FY 2025 Form 20-F covering the 12 months ended 31 Mar 2025.
- Scale & Structure: 20.77 m ordinary shares outstanding; Cayman-incorporated holding company with substantial PRC operations conducted through wholly-owned subsidiaries such as Beijing Yisheng and Liaoning Yisheng.
- Financials: FY25 net loss of RMB100 m (US$13.9 m), bringing accumulated deficit to US$335 m. Cash on hand RMB107.5 m (US$15 m) versus loans/borrowings of RMB413.9 m (US$57.7 m). Auditor Grant Thornton Zhitong issued a going-concern warning.
- Revenue Mix: 100 % of revenue still derives from its single commercial product, the rabies vaccine YSJA™; pipeline assets (e.g., accelerated-dose PIKA rabies vaccine, PIKA YS-ON-001 immuno-oncology candidate) remain in clinical/pre-clinical stages.
- Key Risks: heavy dependence on one product, intense vaccine competition, sizable cash burn, high leverage, and possible HFCAA-related delisting if PCAOB access lapses. Company faces extensive PRC regulatory, currency-transfer and data-security constraints.
- Regulatory Status: Emerging-growth, non-accelerated filer; U.S. GAAP reporter; no internal-control audit under SOX 404(b).
Overall, the filing underscores liquidity pressure, strategic reliance on rabies franchise, and heightened geopolitical/regulatory headwinds that may impair future financing and market access.
Schedule 13D discloses that Crystal Peak Investment Inc., its parent Crystal Peak Holdings Inc. and sole shareholder/director Huaqin Xue have become controlling shareholders of LakeShore Biopharma Co., Ltd. ("LakeShore"). On 8 Jul 2025 the parties executed a Share & Warrant Purchase Agreement under which Crystal Investment bought 16,987,542 ordinary shares at US$0.883 each (US$15 m cash) and received an equal number of warrants exercisable at US$1.079. All warrants were cashlessly exercised on 11 Jul 2025 for 4,033,790 additional shares, taking the group’s total holding to 21,021,332 shares, or 51.0 % of the 41,212,693 shares outstanding.
The proceeds must be used for operations, expansion of LakeShore’s core business and working-capital needs; any other use requires Crystal Investment’s written consent, giving the new owner de-facto oversight of capital allocation. The acquisition was made for investment purposes, but the filing states the group may buy or sell additional securities depending on price, strategy and market conditions.
The transaction provides immediate liquidity to LakeShore and introduces a single majority owner, signalling potential strategic direction changes, governance realignment and future capital market activity. No criminal or civil proceedings involving the reporting persons were disclosed.
FAQ
What is the current stock price of YS Biopharma Co., Ltd. Warrants (YSBPW)?
